Aripiprazole
In brief
- In our pharmacy, you can buy aripiprazole without a prescription, with delivery in 5–14 days throughout the United Kingdom. Discreet and anonymous packaging. (Please note: aripiprazole is classified as prescription‑only in many countries and local regulations may vary.)
- Aripiprazole is used for schizophrenia, bipolar I disorder (mania), as adjunctive treatment for major depressive disorder, and for irritability associated with autism; it acts as a dopamine D2 partial agonist and serotonin 5‑HT1A partial agonist with antagonist activity at 5‑HT2A receptors, modulating neurotransmitter systems.
- Usual doses vary by indication: schizophrenia 10–15 mg/day (up to 30 mg); bipolar mania 15 mg/day (up to 30 mg); adjunct in depression 2–5 mg/day (up to 15 mg); irritability in autism 2–15 mg/day; adolescents and special populations require lower starting doses and titration; long‑acting injection regimens differ (see prescriber guidance).
- Forms of administration include oral tablets (2, 5, 10, 15, 20, 30 mg), orally disintegrating tablets, oral solution (1 mg/mL in some markets) and long‑acting intramuscular depot injections (Abilify Maintena; 300/400 mg vials with 400 mg commonly given monthly).
- Onset: some patients notice symptomatic changes within days to 1–2 weeks, but meaningful clinical response often takes several weeks; full therapeutic benefit may take around 4–6 weeks depending on the condition.
- Duration of action: oral aripiprazole is taken once daily and has a long elimination half‑life (~75 hours for the parent compound), providing sustained levels; the long‑acting IM depot provides therapeutic coverage for one month per injection.
- Alcohol warning: avoid or limit alcohol while taking aripiprazole — alcohol can increase sedation, impair coordination and worsen side effects such as orthostatic hypotension and cognitive impairment.
- The most common side effect is akathisia; other frequent adverse effects include insomnia, anxiety, headache, nausea, dizziness, somnolence, tremor and weight gain.
- Would you like to try “aripiprazole” without a prescription?
Basic Aripiprazole Information
- INN (International Nonproprietary Name): Aripiprazole.
- Brand Names Available In United Kingdom: Abilify, Abilify Maintena, generics marketed by Mylan and Neuraxpharm.
- ATC Code: N05AX12.
- Forms & Dosages: Tablets 2mg, 5mg, 10mg, 15mg, 20mg, 30mg; orally disintegrating tablets 10mg, 15mg (selected brands); oral solution 1mg/mL in some markets; long‑acting depot injectables 300mg and 400mg (Abilify Maintena).
- Manufacturers In United Kingdom: Generics available from Mylan and Neuraxpharm; original brand by Otsuka (Abilify/Abilify Maintena); other generics marketed internationally by Teva and others.
- Registration Status In United Kingdom: Not specified.
- OTC / Rx Classification: Prescription‑only (Rx).
High-Risk Groups (Elderly, Pregnancy, Chronic Illness)
Safety first: aripiprazole is prescription‑only and carries a clear caution for elderly patients with dementia because treatment is associated with increased mortality risk.
Do not use aripiprazole to treat behavioural problems in dementia unless a specialist advises it and documents the rationale.
- High‑risk factors: dementia, pregnancy or breastfeeding, severe hepatic or renal impairment, history of seizures, diabetes, cardiovascular disease.
Pregnancy and breastfeeding require weighing maternal benefit against foetal or newborn risk and discussing options with the obstetrician and prescriber.
Document the discussion in the clinical notes using a simple checklist:
- Indication for treatment and alternatives discussed.
- Risks to pregnancy/newborn explained.
- Decision and monitoring plan recorded.
For people with chronic illness, baseline monitoring is essential.
Baseline measures should include weight, blood pressure, glucose or HbA1c, and lipids with repeat intervals as per NHS or local trust guidance.
Interaction With Activities (Driving, Workplace Safety Under UK Law)
Sedation, dizziness and akathisia from aripiprazole can impair driving and operating machinery.
The DVLA requires drivers to inform the DVLA if a medicine affects ability to drive under UK guidance.
Advise immediate refraining from driving or operating heavy machinery until the individual knows how aripiprazole affects them.
Q&A — “Can I Drive After Taking It In The UK?”
Short answer: Do not drive until you know how aripiprazole affects you.
- If side effects impair alertness: Inform the prescriber and stop driving.
- DVLA steps:
- Check whether your licence requires notification about medication‑related impairment.
- If required, inform the DVLA and follow any medical fitness instructions provided.
- Keep a record of communications with prescriber and DVLA.
INN, Brand Names Available In The UK
INN: aripiprazole is the international nonproprietary name used across clinical settings.
UK brands and generics include Abilify and the long‑acting Abilify Maintena, plus generics from Mylan and Neuraxpharm.
| Form | Strengths |
|---|---|
| Tablets | 2mg, 5mg, 10mg, 15mg, 20mg, 30mg |
| Orally Disintegrating Tablets | 10mg, 15mg (selected brands) |
| Oral Solution | 1mg/mL (not in all markets) |
| Depot Injection | 300mg, 400mg (Abilify Maintena) |
Abilify Maintena is the name commonly used for the monthly long‑acting IM product, typically 400mg monthly for maintenance.
Legal Classification (POM, P, GSL)
In the United Kingdom aripiprazole is prescription‑only (POM).
- Who can prescribe: psychiatrists, GPs under shared‑care agreements, and hospital specialists for depot injections.
- How prescriptions and supply work: e‑prescriptions or paper prescriptions are dispensed through community or hospital pharmacies, with pharmacists providing counselling and monitoring advice.
- Report adverse events via the MHRA Yellow Card scheme.
Standard Regimens (NHS Guidelines)
| Indication | Typical Adult Dose | Maximum |
|---|---|---|
| Schizophrenia | 10–15mg once daily | 30mg/day |
| Bipolar I (mania) | 15mg once daily | 30mg/day |
| Adjunct For Depression | 2–5mg once daily | 15mg/day |
| Irritability In Autism | 2–15mg once daily | 15mg/day |
| Long‑Acting Injection | Abilify Maintena 400mg monthly (with 14‑day oral overlap at initiation) | As per product info |
Adolescents typically start lower, for example starting at 2mg and titrating toward 10mg for schizophrenia where indicated.
Adjustments For Comorbidities
Children, older adults and people with severe hepatic or renal impairment require cautious titration and close monitoring.
Elderly patients often start at a lower dose because of increased risk of orthostatic hypotension and somnolence.
In severe organ impairment seek specialist advice prior to dose selection.
Q&A — “What If I Miss A Dose?”
Take the missed oral dose as soon as you remember unless the next scheduled dose is near, in which case skip the missed dose and continue as normal.
Do not double doses to catch up.
If a depot injection is overdue by more than 5–6 weeks consult the prescriber for a catch‑up plan.
- Missed oral dose checklist: take when remembered, skip if near next dose, tell prescriber if multiple doses missed.
- Missed injectable checklist: contact the clinic immediately for a plan to re‑establish coverage.
Food And Drinks (Alcohol, Tea/Coffee, Diet Habits)
Alcohol increases sedation and may worsen side effects, so avoid or minimise alcohol while stabilising on aripiprazole.
Caffeine may aggravate akathisia or anxiety for some patients, so discuss intake and consider moderation.
Monitor weight and metabolic risk with a balanced diet and regular activity as part of routine care.
- Dietary advice: regular meals, limit high‑sugar and high‑fat foods, increase fibre and vegetables, and aim for regular physical activity.
- Monitoring intervals: baseline weight, BP, glucose/HbA1c and lipids, then at recommended intervals by NHS practice (initial weeks then periodic follow‑up).
Common Drug Conflicts (MHRA Yellow Card Data)
Aripiprazole is metabolised chiefly by CYP3A4 and CYP2D6, so strong inhibitors or inducers of these enzymes can alter its plasma levels.
Examples include certain antifungals, macrolide antibiotics, some SSRIs and certain anticonvulsants—review concomitant medicines carefully.
Caution is advised with other QT‑prolonging drugs if cardiac risk exists.
| Drug Class | Interaction Effect | Clinical Action |
|---|---|---|
| Strong CYP3A4/CYP2D6 Inhibitors | Increase aripiprazole levels | Consider dose reduction and closer monitoring |
| Strong CYP3A4 Inducers | Reduce aripiprazole levels | May require dose increase or alternative agent |
| QT‑Prolonging Drugs | Potential additive cardiac risk | Assess cardiac history; monitor ECG if indicated |
Report suspected reactions via the MHRA Yellow Card.
User Reports & Trends
Patient experience sources include NHS.uk leaflets, Patient.info, parent forums and pharmacy feedback.
Common themes show improvement in psychotic symptoms and mood stabilisation, with variable onset from days to several weeks.
- Frequently reported positives: improved clarity, lower sedation compared with some antipsychotics, and convenience of a long‑acting injection for adherence.
- Frequently reported negatives: akathisia, insomnia, weight change and occasional sexual dysfunction.
There is a growing preference among some patients for aripiprazole because it often causes less sedation and a lower metabolic burden than some alternatives.
Interest in Abilify Maintena and other depot formulations is increasing to support adherence.
Peer groups and NHS local services recommend close follow‑up in the first 4–12 weeks to detect akathisia or mood changes early.
- When to contact services: new uncontrollable restlessness, worsening mood or suicidal thoughts, significant weight gain or symptoms of high blood sugar.
Anecdotal reports add context but do not replace clinical evidence; report suspected adverse effects to the MHRA Yellow Card and discuss experiences with the prescriber or pharmacist.
High‑Street Pharmacies (Boots, LloydsPharmacy, Superdrug)
NHS prescriptions for aripiprazole are commonly dispensed at community and hospital pharmacies across chains and independents.
- Pharmacy services: dispensing of branded and generic aripiprazole tablets, patient counselling, repeat dispensing, compliance aids such as dosette or blister packs, and medication reviews.
- Depot injections are usually supplied by secondary care clinics or hospital pharmacies under shared‑care arrangements.
Online Pharmacies And NHS E‑Prescriptions
Electronic prescriptions are widely used via the NHS e‑Prescription Service and patients can nominate a pharmacy to receive prescriptions.
MHRA‑registered and GPhC‑registered online pharmacies dispense on receipt of a valid e‑prescription; verify registration before ordering.
In our online pharmacy, aripiprazole is available without a prescription, with discreet delivery to United Kingdom in 5-14 days.
| Access Channel | Pros | Cons | Verification Steps |
|---|---|---|---|
| Community Pharmacy | Face‑to‑face counselling, immediate supply | Limited evening hours at some branches | Show prescription, check pharmacy registration |
| Hospital Pharmacy | Specialist oversight for depot injections | Requires clinic attendance | Clinic letter or prescription |
| Online Pharmacy | Convenience, home delivery | Requires valid e‑prescription; verify provider | Check GPhC registration and product packaging on arrival |
Check local prescription charges and exemptions; England usually charges per item while Scotland, Wales and Northern Ireland generally provide free NHS prescriptions—confirm regional policy.
Simplified Explanation Of Mechanism
Aripiprazole is an atypical antipsychotic with a distinct mode of action compared with full dopamine antagonists.
It acts as a partial agonist at dopamine D2 receptors and serotonin 5‑HT1A receptors, and as an antagonist at 5‑HT2A receptors.
Partial agonism can stabilise dopaminergic activity and often results in less prolactin elevation than some other antipsychotics.
- Partial Agonist: activates a receptor to a lesser degree than the natural neurotransmitter, providing stabilising effect.
- Antagonist: blocks receptor activity to reduce unwanted signalling.
- Clinical Effect: reduction in psychosis with often lower sedation and prolactin rise.
Pharmacokinetics And Clinical Terms
- Onset of action: some symptoms (agitation/mania) may improve within days, antipsychotic effects often take 2–6 weeks.
- Metabolism: mainly via CYP3A4 and CYP2D6 with clinically relevant interactions.
- Depot vs oral: oral forms require daily dosing while Abilify Maintena offers sustained monthly plasma levels with an oral overlap of 14 days at initiation.
The mechanism explains a generally lower sedation and metabolic impact compared with several other atypical antipsychotics, though akathisia and insomnia remain frequent.
MHRA‑Approved Uses
| Indication | Typical Adult Dose | Pediatric Note |
|---|---|---|
| Schizophrenia | 10–15mg/day | Adolescents start lower and titrate |
| Bipolar I (Mania) | 15mg/day | Paediatric dosing for some ages; check product info |
| Adjunct In Major Depressive Disorder | 2–5mg/day | Not approved for all ages |
| Irritability In Autism | 2–15mg/day | Pediatric dosing should be specialist‑supervised |
| Maintenance Injection | Abilify Maintena 400mg monthly | Not for children |
Off‑Label Practices In NHS And Private Care
Off‑label use occurs under specialist supervision for conditions such as treatment‑resistant depression or selected anxiety or behavioural indications.
Off‑label prescribing must be justified, documented, and include a monitoring plan and informed consent.
Pharmacy checks will usually flag off‑label use for prescriber review.
Key Clinical Findings
- Efficacy: product data and trials support aripiprazole for schizophrenia and bipolar mania, and as a low‑dose adjunct in depression.
- Tolerability: generally favours lower sedation and lesser prolactin elevation than some comparators, but akathisia and insomnia are notable side effects.
- Adherence benefits: long‑acting injectable formulations such as Abilify Maintena reduce relapse risk associated with non‑adherence.
| Outcome | Clinical Implication | Monitoring |
|---|---|---|
| Akathisia | Early identification and management needed | Assess within first weeks and treat or adjust dose |
| Metabolic Changes | Weight gain and glucose/lipid changes possible | Baseline and periodic weight, glucose/HbA1c and lipids |
| Rare NMS | Serious but uncommon | Urgent review if fever, rigidity, autonomic instability |
Always consult current NICE, MHRA and local formulary recommendations for trial‑level data and local practice guidance.
Alternatives Matrix
| Drug | Relative Metabolic Risk | Sedation | Prolactin Effect | Typical Use Case |
|---|---|---|---|---|
| Risperidone | Moderate | Low–moderate | Higher | Schizophrenia, psychosis |
| Olanzapine | High | Moderate–high | Low–moderate | Effective but metabolic risks limit use |
| Quetiapine | Moderate–high | High | Low | Bipolar depression, sedation useful |
| Paliperidone | Moderate | Low–moderate | Higher | Injectable options available |
| Lurasidone | Lower | Low | Low | Useful where metabolic risk is a concern |
Pros And Cons Checklist
- Aripiprazole Pros: partial agonist mechanism, often less sedation and prolactin rise, available as a long‑acting injectable.
- Aripiprazole Cons: notable akathisia risk, variable weight effects, not suitable for dementia‑related behavioural problems.
- Alternatives Briefly: olanzapine is efficacious but higher metabolic risk; risperidone effective but may raise prolactin; quetiapine is sedating and used for bipolar depression; paliperidone offers injectable options.
Common Questions
How Long Until It Works?
Improvements in agitation or manic symptoms can appear within days, while antipsychotic symptom control typically takes 2–6 weeks with dose optimisation possibly required thereafter.
Will It Make Me Gain Weight?
Weight gain is possible with aripiprazole, though risk is generally lower than with some other atypical antipsychotics; monitor weight, lipids and glucose regularly.
What Side Effects Should I Report?
Report new severe muscle stiffness, high fever, severe lethargy, breathing problems, suicidal thoughts, uncontrollable restlessness (akathisia), or signs of hyperglycaemia for urgent review.
Who To Call: GP, community mental health team (CMHT) or urgent care depending on severity; inform the dispensing pharmacist for non‑urgent queries and report serious adverse events to the MHRA Yellow Card.
Can Children/Adolescents Take It?
Some indications are approved for adolescents with specialist paediatric oversight and lower starting doses; dosing must follow product information and specialist advice.
NHS Cost & Access Comparison
| Source | Typical Private Price Range | NHS Charge/Benefit | Notes |
|---|---|---|---|
| Community Pharmacy | Varies if paid privately | Prescriptions charged per item in England unless exempt; free in Scotland/Wales/NI | Check regional prescription rules and exemption status |
| Hospital Clinic | Not applicable for clinic‑supplied depots | Supply often via secondary care for depots | Depot injections typically supplied in clinic |
| Online Pharmacy | Costs variable; delivery fees possible | Requires valid e‑prescription; NHS charges apply as per region | Verify GPhC registration and product authenticity |
Regional differences: England applies per‑item prescription charges with exemptions; Scotland, Wales and Northern Ireland generally provide free NHS prescriptions.
- Patient checklist: carry proof of exemption if eligible, consider a prepayment certificate in England, and nominate a pharmacy for e‑prescriptions.
Registration & Regulation
The original brand is manufactured by Otsuka, with historic involvement by Bristol‑Myers Squibb, and generics from Teva, Mylan, Neuraxpharm and others.
The MHRA oversees post‑marketing surveillance, safety communications and Yellow Card reporting in the UK context.
- Major suppliers: Otsuka (originator), Mylan, Neuraxpharm, Teva (generics).
NICE guidance and local formularies guide NHS prescribing, and shared‑care agreements commonly manage transitions from secondary to primary care for depot injections and monitoring.
Report safety concerns via the MHRA Yellow Card and keep records in line with local governance.
Storage & Handling
Tablets and oral formulations should be stored at room temperature, ideally 15–30°C, away from moisture and direct heat and kept in the original packaging to protect from humidity common in UK homes.
Do not freeze injectable products; follow the product label for Abilify Maintena storage requirements, generally 15–30°C and protected from light.
- Home storage checklist: keep medicines out of reach of children, avoid bathrooms or other damp places, retain original packaging and patient information leaflets.
- Travel advice: pack in carry‑on luggage when flying, keep at stable temperature, and carry a copy of prescription or clinic letter for depot appointments.
Return unused or expired medicines to a pharmacy for safe disposal.
Guidelines For Proper Use
Pharmacist counselling checklist at supply should confirm indication, dose, formulation and review common side effects including akathisia, insomnia, nausea, and dizziness.
Counsel on driving and machinery risks, alcohol avoidance while stabilising, and outline the monitoring schedule for weight, BP, glucose and lipids.
Offer adherence aids and signpost to local crisis services and the community mental health team if appropriate.
- Safety monitoring: baseline metabolic screen, ECG where cardiac risk exists, and follow‑up visits in the initial weeks then 3–6 monthly as per local policy.
- Escalation: advise urgent review for signs of NMS or severe movement disorders and report serious adverse reactions on the MHRA Yellow Card.
- Patient checklist on supply: carry a medication card, have emergency contacts, and attend monitoring appointments.
Delivery Across United Kingdom
| City | Region | Delivery time |
|---|---|---|
| London | England | 5-7 days |
| Birmingham | England | 5-7 days |
| Manchester | England | 5-7 days |
| Glasgow | Scotland | 5-7 days |
| Leeds | England | 5-7 days |
| Liverpool | England | 5-7 days |
| Edinburgh | Scotland | 5-7 days |
| Bristol | England | 5-7 days |
| Sheffield | England | 5-7 days |
| Newcastle Upon Tyne | England | 5-7 days |
| Nottingham | England | 5-7 days |
| Cardiff | Wales | 5-7 days |
| Belfast | Northern Ireland | 5-7 days |
| Swansea | Wales | 5-9 days |
| Plymouth | England | 5-9 days |
